fluorouracil

(redirected from Efudex)
Also found in: Dictionary, Thesaurus, Medical.

fluorouracil:

see metabolitemetabolite,
organic compound that is a starting material in, an intermediate in, or an end product of metabolism. Starting materials are substances, usually small and of simple structure, absorbed by the organism as food. These include the vitamins and essential amino acids.
..... Click the link for more information.
.

fluorouracil

[¦flu̇r·ō′yu̇r·ə‚sil]
(pharmacology)
C4H3FN2O2 Crystals that decompose at 282-283°C; used as an antineoplastic drug and as an inhibitor of deoxyribonucleic acid synthesis. Also known as 2,4-dioxo-5-fluoropyrimidine; 5-FU.
References in periodicals archive ?
Efudex is contraindicated in women who are, or may become, pregnant during therapy because of potential hazards to the fetus.
Efudex, Cesamet, Kinerase, Mestinon, Zelapar, Migranal, Bedoyecta, Solcoseryl and Bisocard are trademarks or registered trademarks of Valeant Pharmaceuticals International or its related companies.
The decline in Efudex sales primarily reflects the pull-through of inventory from the launch of the company's generic product at the end of 2006.
Several promoted products performed well in Europe, including Mestinon, Efudex, Solcoseryl[TM] and Bisocard[TM].
wholesale inventory reduction measures and increased sales of Efudex, due to stronger demand in the first quarter of 2004.
Top products in North America in the third quarter were Diastat, Efudex, Infergen, Cesamet, Kinerase and Zelapar[R].
The region reported increased sales in the quarter of Efudex, Kinerase and Cesamet, which were offset by declines in sales of Diastat and Migranal in the period, along with decreased sales of non-promoted products.
Excluding acquired products, sales in North America increased two percent in the quarter, primarily due to increased sales of Kinerase, Cesamet and Virazole(R), partially offset by decreased sales of Efudex in the quarter.
Increases in both periods were primarily due to the growth of acquired products, particularly Diastat and Migranal, and from the promoted products, Kinerase, Efudex and Cesamet.
Sales of Efudex were up 17 % to $7 million from last year's third quarter.
Contributing to this strong performance was a higher demand for the company's dermatology products, including Efudex, for pre-cancerous skin lesions, and hyper-pigmentation products.